UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2019
CORVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37719 | 46-4670809 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
863 Mitten Road, Suite 102
Burlingame, CA 94010
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 900-4520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, Par Value $0.0001 per share | CRVS | Nasdaq Global Market |
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 20, 2019, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) at 863 Mitten Road, Suite 102, Burlingame, California 94010. Only stockholders of record at the close of business on April 24, 2019, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 29,326,900 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 27,021,417 shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2019.
The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal No. 1 — Election of Directors
The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2022 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal.
| Class III Director Nominees | Votes For | Votes Withheld | Broker Non-Votes | |||
| Ian T. Clark | 17,741,792 | 7,185,155 | 2,094,470 | |||
| Elisha P. (Terry) Gould III | 22,535,894 | 2,391,053 | 2,094,470 | |||
| Peter Thompson, M.D. | 22,531,875 | 2,395,072 | 2,094,470 |
Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
| Votes For | Votes Against | Abstain | |||
| 24,712,924 | 4,403 | 2,304,090 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORVUS PHARMACEUTICALS, INC. | |||
| Date: June 21, 2019 | By: | /s/ Leiv Lea | |
| Leiv Lea | |||
| Chief Financial Officer | |||